Global Erbium-169 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Erbium-169 market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
In 2025, global erbium-169 production is estimated at approximately 18,500 mCi, with an average global market price of about US$420 per mCi of erbium-169. Total global erbium-169 production capacity is projected to reach approximately 26,000 mCi by 2025, with an industry average gross margin of approximately 52%. Erbium-169 is an artificial radioactive isotope of erbium, with atomic number 68 and mass number 169. It is virtually non-existent in nature and must be produced through nuclear reactor irradiation. Its half-life is approximately 9.4 days, primarily decaying into stable thulium-169 (¹⁶⁹Tm) via β⁻ decay. The β particles released by erbium-169 have a short penetration distance, allowing for the deposition of radiation energy within a relatively small area. Therefore, it is suitable for local treatment, particularly for radiation-induced synovectomy of small joints such as the fingers, wrists, and toes. It can also be used in brachytherapy research, radiation biology experiments, and radioactive tracing studies. The International Atomic Energy Agency (IAEA) lists erbium-169 as a radionuclide suitable for small joint treatment.
The upstream of the erbium-169 industry chain mainly includes the mining and separation of natural erbium resources, the preparation of high-purity erbium oxide or metallic erbium, the enrichment of stable erbium-168 isotopes, and research reactor irradiation services. The mainstream production route uses enriched erbium-168 targets as raw materials to produce erbium-169 through the ¹⁶⁸Er(n,γ)¹⁶⁹Er reaction in a nuclear reactor. Since the abundance of erbium-168 in natural erbium is low, using enriched targets helps improve the activity of the target nuclide and production efficiency. The core barriers in this stage are concentrated in isotope separation, high-purity target processing, neutron flux resources, irradiation program management, and radiation safety permitting. The midstream includes target irradiation, cooling and transport, radiochemical separation and purification, activity and nuclide purity testing, drug formulation preparation, and sealed or unsealed radioactive source encapsulation. For medical applications, erbium-169 is typically formulated as a colloidal or particulate suspension, allowing it to remain primarily in the synovial region after injection into the joint cavity; research and brachytherapy applications may further develop it into specific forms of radioactive sources. Manufacturing companies need to establish aseptic manufacturing, quality control, dosage calibration, shielded packaging, and cold chain or timed transportation systems that meet the requirements for radiopharmaceuticals. Due to its short half-life of only about 9.4 days, the product cannot be stored for long periods, and production scheduling must be closely aligned with hospital usage. The core downstream applications of erbium-169 are in nuclear medicine, rheumatology, orthopedics, and specialized radiotherapy centers, primarily for radiation-induced synovectomy of small joints in patients with rheumatoid arthritis, hemophilic arthritis, and other chronic synovitis. Its advantage lies in the smaller range of beta rays, making it suitable for irradiating locally affected synovium while minimizing impact on surrounding healthy tissues. Other potential demands come from brachytherapy, the development of radioactive microspheres or implantable sources, dosimetry studies, and nuclear medicine research institutions.
The erbium-169 market is primarily driven by the demand for precise radionuclide therapy for small joints. Erbium-169 has a half-life of approximately 9.4 days, low beta-ray energy, and short tissue penetration distance, making it suitable for radiation-induced synovectomy of small joints such as the fingers, wrists, and toes. With increasing demand for minimally invasive treatments, local administration, and reduced systemic side effects among patients with rheumatoid arthritis, hemophilic arthritis, and chronic synovitis, erbium-169 citrate and other formulations still have clear clinical value. Currently, demand is mainly concentrated in the European market, including Germany, France, and Switzerland, which have mature nuclear medicine diagnostic and treatment systems.
Advances in high-flux research reactors and isotope separation technology are important factors driving the increase in erbium-169 supply capacity. Erbium-169 is primarily produced through neutron irradiation of erbium-168 enriched targets. However, erbium-168 has a low neutron capture cross-section and may form impurities such as erbium-165, erbium-171, and ytterbium-169, limiting the specific activity and nuclide purity of the product. In the future, the industry will strengthen high-abundance erbium-168 targets, target recycling, high-neutron flux irradiation, offline mass separation, and multi-stage radiochemical purification technologies to improve the yield per unit target and reduce impurity levels.
Downstream applications are gradually expanding from traditional radioactive synovectomy to targeted radionuclide therapy and research on the treatment of small lesions. Erbium-169's lower electron energy allows for more localized energy deposition in small tumors or cell clusters, and its chemical properties are similar to radioactive lanthanides such as lutetium-177, allowing for drug conjugation studies using chelation systems such as DOTA. Therefore, erbium-169 has certain research and development potential in small-volume tumors, micrometastases, postoperative residual lesions, and novel radioligand therapy. However, it is currently still in the preclinical research or early translation stage and is unlikely to replace mature therapeutic radionuclides in the short term.
Report Scope
This report is a detailed and comprehensive analysis for global Erbium-169 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Erbium-169 market size and forecasts, in consumption value ($ Million), sales quantity (mCi), and average selling prices (US$/mCi), 2021-2032
Global Erbium-169 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (mCi), and average selling prices (US$/mCi), 2021-2032
Global Erbium-169 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (mCi), and average selling prices (US$/mCi), 2021-2032
Global Erbium-169 market shares of main players, shipments in revenue ($ Million), sales quantity (mCi), and ASP (US$/mCi), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Erbium-169
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Erbium-169 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ORNL, Rosatom, Neonest AB(BuyIsotope), SCK CEN, Trace Sciences International, Smolecule, AMT Isotopes, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Erbium-169 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
Reactor Production
Accelerator Production
Market segment by Raw Material
Natural Erbium Sputtering Targets
Erbium-168 Enriched Sputtering Targets
Market segment by Specific Activity
Low Specific Activity Erbium-169
Medium Specific Activity Erbium-169
High Specific Activity Erbium-169
Market segment by Chemical Form
Erbium-169 Chloride
Erbium-169 Citrate Colloid
Erbium-169 Phosphate
Erbium-169 Chelate
Erbium-169 Oxide or Solid Material
Market segment by Application
Nuclear Medicine
Industrial Tracer
Scientific Research
Major players covered
ORNL
Rosatom
Neonest AB(BuyIsotope)
SCK CEN
Trace Sciences International
Smolecule
AMT Isotopes
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Erbium-169 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Erbium-169, with price, sales quantity, revenue, and global market share of Erbium-169 from 2021 to 2026.
Chapter 3, the Erbium-169 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Erbium-169 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Erbium-169 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Erbium-169.
Chapter 14 and 15, to describe Erbium-169 sales channel, distributors, customers, research findings and conclusion.